Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Momenta Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Momenta Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Momenta Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Momenta Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Momenta Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Momenta Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Momenta Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Momenta Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Momenta Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Momenta Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Momenta Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Momenta Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Momenta Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Momenta Pharmaceuticals, Inc. Snapshot 5 Momenta Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Momenta Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Momenta Pharmaceuticals, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Momenta Pharmaceuticals, Inc. - Pipeline Products Glance 13 Momenta Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 13 Phase I Products/Combination Treatment Modalities 13 Momenta Pharmaceuticals, Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 Momenta Pharmaceuticals, Inc. - Drug Profiles 16 M-402 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Antibody for Autoimmune Disorders and Inflammation 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 M-834 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 M-923 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 M-511 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Momenta Pharmaceuticals, Inc. - Pipeline Analysis 21 Momenta Pharmaceuticals, Inc. - Pipeline Products by Target 21 Momenta Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 22 Momenta Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 23 Momenta Pharmaceuticals, Inc. - Recent Pipeline Updates 24 Momenta Pharmaceuticals, Inc. - Dormant Projects 25 Momenta Pharmaceuticals, Inc. - Company Statement 26 Momenta Pharmaceuticals, Inc. - Locations And Subsidiaries 31 Head Office 31 Other Locations & Subsidiaries 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 33 Disclaimer 33
List of Tables Momenta Pharmaceuticals, Inc., Key Information 5 Momenta Pharmaceuticals, Inc., Key Facts 5 Momenta Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8 Momenta Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9 Momenta Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10 Momenta Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 11 Momenta Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12 Momenta Pharmaceuticals, Inc. - Phase I, 2014 13 Momenta Pharmaceuticals, Inc. - Preclinical, 2014 14 Momenta Pharmaceuticals, Inc. - Discovery, 2014 15 Momenta Pharmaceuticals, Inc. - Pipeline by Target, 2014 21 Momenta Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 22 Momenta Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 23 Momenta Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 24 Momenta Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 25 Momenta Pharmaceuticals, Inc., Subsidiaries 31
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.